Literature DB >> 26230235

Update in Lung Cancer 2014.

Avrum Spira1, Balazs Halmos2, Charles A Powell3.   

Abstract

In the past 2 years, lung cancer research and clinical care have advanced significantly. Advancements in the field have improved outcomes and promise to lead to further reductions in deaths from lung cancer, the leading cause of cancer death worldwide. These advances include identification of new molecular targets for personalized targeted therapy, validation of molecular signatures of lung cancer risk in smokers, progress in lung tumor immunotherapy, and implementation of population-based lung cancer screening with chest computed tomography in the United States. In this review, we highlight recent research in these areas and challenges for the future.

Entities:  

Keywords:  biomarkers; chest computed tomography screening; lung cancer; lung immunotherapy; targeted therapy

Mesh:

Substances:

Year:  2015        PMID: 26230235      PMCID: PMC4584253          DOI: 10.1164/rccm.201504-0756UP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  100 in total

1.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Authors:  Shirish M Gadgeel; Leena Gandhi; Gregory J Riely; Alberto A Chiappori; Howard L West; Michele C Azada; Peter N Morcos; Ruey-Min Lee; Linta Garcia; Li Yu; Frederic Boisserie; Laura Di Laurenzio; Sophie Golding; Jotaro Sato; Shumpei Yokoyama; Tomohiro Tanaka; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2014-08-18       Impact factor: 41.316

2.  EBUS-centred versus EUS-centred mediastinal staging in lung cancer: a randomised controlled trial.

Authors:  Hyo Jae Kang; Bin Hwangbo; Geon-Kook Lee; Byung-Ho Nam; Hyun-Sung Lee; Moon Soo Kim; Jong Mog Lee; Jae Ill Zo; Hee Seok Lee; Ji-Youn Han
Journal:  Thorax       Date:  2013-10-30       Impact factor: 9.139

3.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

4.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

5.  Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.

Authors:  Shervin M Shirvani; Jing Jiang; Joe Y Chang; James Welsh; Anna Likhacheva; Thomas A Buchholz; Stephen G Swisher; Benjamin D Smith
Journal:  JAMA Surg       Date:  2014-12       Impact factor: 14.766

6.  Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial.

Authors:  Nanda Horeweg; Carlijn M van der Aalst; Erik Thunnissen; Kristiaan Nackaerts; Carla Weenink; Harry J M Groen; Jan-Willem J Lammers; Joachim G Aerts; Ernst T Scholten; Joost van Rosmalen; Willem Mali; Matthijs Oudkerk; Harry J de Koning
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

7.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

8.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Authors:  Annette O Walter; Robert Tjin Tham Sjin; Henry J Haringsma; Kadoaki Ohashi; Jing Sun; Kwangho Lee; Aleksandr Dubrovskiy; Matthew Labenski; Zhendong Zhu; Zhigang Wang; Michael Sheets; Thia St Martin; Russell Karp; Dan van Kalken; Prasoon Chaturvedi; Deqiang Niu; Mariana Nacht; Russell C Petter; William Westlin; Kevin Lin; Sarah Jaw-Tsai; Mitch Raponi; Terry Van Dyke; Jeff Etter; Zoe Weaver; William Pao; Juswinder Singh; Andrew D Simmons; Thomas C Harding; Andrew Allen
Journal:  Cancer Discov       Date:  2013-09-24       Impact factor: 39.397

Review 9.  Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Frank C Detterbeck; Peter J Mazzone; David P Naidich; Peter B Bach
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

Authors:  A Vaishnavi; M Capelletti; P A Jänne; R C Doebele; A T Le; S Kako; M Butaney; D Ercan; S Mahale; K D Davies; D L Aisner; A B Pilling; E M Berge; J Kim; H Sasaki; S Park; G Kryukov; L A Garraway; Peter S Hammerman; J Haas; S W Andrews; D Lipson; P J Stephens; V A Miller; M Varella-Garcia
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

View more
  13 in total

1.  The action and mechanism of myrislignan on A549 cells in vitro and in vivo.

Authors:  XinGang Lu; Liu Yang; JingXian Chen; JiAn Zhou; XiaoDan Tang; YingGang Zhu; HongFu Qiu; Jie Shen
Journal:  J Nat Med       Date:  2016-08-04       Impact factor: 2.343

2.  A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.

Authors:  Xin He; Yaqian Chi; Jingcui Peng; Wenxia Hu; Cuimin Ding; Bin Li
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

3.  Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.

Authors:  I-Shou Chang; Shih Sheng Jiang; James Chih-Hsin Yang; Wu-Chou Su; Li-Hsin Chien; Chin-Fu Hsiao; Jih-Hsiang Lee; Chih-Yi Chen; Chung-Hsing Chen; Gee-Chen Chang; Zhaoming Wang; Fang-Yi Lo; Kuan-Yu Chen; Wen-Chang Wang; Yuh-Min Chen; Ming-Shyan Huang; Ying-Huang Tsai; Yu-Chun Su; Wan-Shan Hsieh; Wen-Chi Shih; Shwn-Huey Shieh; Tsung-Ying Yang; Qing Lan; Nathaniel Rothman; Chien-Jen Chen; Stephen J Chanock; Pan-Chyr Yang; Chao A Hsiung
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

4.  The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics.

Authors:  Ting-Yuan David Cheng; Susanna M Cramb; Peter D Baade; Danny R Youlden; Chukwumere Nwogu; Mary E Reid
Journal:  J Thorac Oncol       Date:  2016-06-27       Impact factor: 15.609

5.  Lung Cancer Diagnosis by Fine Needle Aspiration Is Associated With Reduction in Resection of Nonmalignant Lung Nodules.

Authors:  Julie A Barta; Claudia I Henschke; Raja M Flores; Rowena Yip; David F Yankelevitz; Charles A Powell
Journal:  Ann Thorac Surg       Date:  2017-03-06       Impact factor: 5.102

6.  Molecular Role of EGFR-MAPK Pathway in Patchouli Alcohol-Induced Apoptosis and Cell Cycle Arrest on A549 Cells In Vitro and In Vivo.

Authors:  XinGang Lu; Liu Yang; ChengHua Lu; ZhenYu Xu; HongFu Qiu; JiaJia Wu; JingWen Wang; JiaFeng Tong; Yin Zhu; Jie Shen
Journal:  Biomed Res Int       Date:  2016-10-17       Impact factor: 3.411

Review 7.  Smoking and Lung Cancer: A Geo-Regional Perspective.

Authors:  Zahraa Rahal; Shaza El Nemr; Ansam Sinjab; Hassan Chami; Arafat Tfayli; Humam Kadara
Journal:  Front Oncol       Date:  2017-09-01       Impact factor: 6.244

Review 8.  Utilization of lung cancer cell lines for the study of lung cancer stem cells.

Authors:  Yuyi Wang; Ming Jiang; Chi Du; Yang Yu; Yanyang Liu; Mei Li; Feng Luo
Journal:  Oncol Lett       Date:  2018-03-14       Impact factor: 2.967

Review 9.  Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.

Authors:  Melina Marmarelis; Jeffrey C Thompson; Charu Aggarwal; Tracey L Evans; Erica Carpenter; Roger B Cohen; Corey J Langer; Joshua Bauml
Journal:  Ann Transl Med       Date:  2017-09

10.  LINE-1 couples EMT programming with acquisition of oncogenic phenotypes in human bronchial epithelial cells.

Authors:  Elsa M Reyes-Reyes; Ivan Aispuro; Marco A Tavera-Garcia; Matthew Field; Sara Moore; Irma Ramos; Kenneth S Ramos
Journal:  Oncotarget       Date:  2017-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.